Prime Medicine
David Van Goor is an experienced intellectual property professional currently serving as the Vice President of Intellectual Property at Prime Medicine, Inc. since January 2022, having previously held the position of Senior Director of Intellectual Property at the same company. Prior to this role, David worked at Merck as Director of Patents from May 2019 to January 2022. David's earlier positions include Associate and Patent Agent at Wilson Sonsini Goodrich & Rosati and Graduate Student at Yale University. David's educational background includes a Juris Doctor from The George Washington University Law School, a PhD and an MS in Molecular, Cellular & Developmental Biology from Yale University, and a BS in Biological Sciences from Carnegie Mellon University.
This person is not in any teams
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.